Peter Ulrichts

2.2k total citations
33 papers, 906 citations indexed

About

Peter Ulrichts is a scholar working on Immunology, Radiology, Nuclear Medicine and Imaging and Neurology. According to data from OpenAlex, Peter Ulrichts has authored 33 papers receiving a total of 906 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Immunology, 13 papers in Radiology, Nuclear Medicine and Imaging and 11 papers in Neurology. Recurrent topics in Peter Ulrichts's work include Monoclonal and Polyclonal Antibodies Research (13 papers), Myasthenia Gravis and Thymoma (11 papers) and Immune Response and Inflammation (6 papers). Peter Ulrichts is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (13 papers), Myasthenia Gravis and Thymoma (11 papers) and Immune Response and Inflammation (6 papers). Peter Ulrichts collaborates with scholars based in Belgium, United States and Netherlands. Peter Ulrichts's co-authors include Jan Tavernier, Hans de Haard, Frank Peelman, Torsten Dreier, E. Sally Ward, Nicolas Leupin, Dominiek Catteeuw, Erik Hofman, Rudi Beyaert and Peter Verheesen and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Peter Ulrichts

31 papers receiving 890 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Ulrichts Belgium 13 282 241 192 186 154 33 906
Balaji Balasa United States 17 770 2.7× 181 0.8× 225 1.2× 156 0.8× 262 1.7× 30 1.4k
Barbara A. Vance United States 17 879 3.1× 91 0.4× 407 2.1× 224 1.2× 213 1.4× 26 1.4k
Yuko Kozono Japan 14 820 2.9× 20 0.1× 279 1.5× 151 0.8× 85 0.6× 18 1.2k
Toshimasa Nakagawa Japan 16 424 1.5× 37 0.2× 486 2.5× 93 0.5× 75 0.5× 29 1.2k
Maria Hinterberger Germany 12 1.0k 3.7× 65 0.3× 211 1.1× 36 0.2× 50 0.3× 21 1.3k
Roberto González‐Amaro Mexico 14 339 1.2× 43 0.2× 214 1.1× 60 0.3× 86 0.6× 21 785
Elinor Lee United States 11 173 0.6× 48 0.2× 285 1.5× 33 0.2× 68 0.4× 21 659
D. Ockert Germany 15 345 1.2× 20 0.1× 358 1.9× 58 0.3× 25 0.2× 47 1.2k
Anna Lena Illert Germany 15 115 0.4× 32 0.1× 338 1.8× 40 0.2× 118 0.8× 55 830
Claudia Müller Germany 15 558 2.0× 21 0.1× 216 1.1× 89 0.5× 43 0.3× 24 917

Countries citing papers authored by Peter Ulrichts

Since Specialization
Citations

This map shows the geographic impact of Peter Ulrichts's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Ulrichts with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Ulrichts more than expected).

Fields of papers citing papers by Peter Ulrichts

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Ulrichts. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Ulrichts. The network helps show where Peter Ulrichts may publish in the future.

Co-authorship network of co-authors of Peter Ulrichts

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Ulrichts. A scholar is included among the top collaborators of Peter Ulrichts based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Ulrichts. Peter Ulrichts is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Warang, Prajakta, Gagandeep Singh, Mahan Moshir, et al.. (2025). Impact of FcRn antagonism on vaccine-induced protective immune responses against viral challenge in COVID-19 and influenza mouse vaccination models. Human Vaccines & Immunotherapeutics. 21(1). 2470542–2470542. 3 indexed citations
2.
Cocco, Mario, Christopher B. Cooper, Mahan Moshir, et al.. (2025). Effects of efgartigimod treatment on humoral and cellular immune responses: analysis of T-cell-dependent antibody response in cynomolgus monkeys. Journal of Immunotoxicology. 22(1). 2459934–2459934. 4 indexed citations
3.
Ma, Guanglong, Andrew R. Crowley, Eef Parthoens, et al.. (2024). Differential effects of FcRn antagonists on the subcellular trafficking of FcRn and albumin. JCI Insight. 9(10). 12 indexed citations
4.
Matthijssens, Filip, et al.. (2024). Effect of Efgartigimod IV on Immature Platelet Count Fraction in Primary Immune Thrombocytopenia. Blood. 144(Supplement 1). 5443–5443. 1 indexed citations
5.
Ostrovskaya, Olga, et al.. (2023). Efgartigimod: Clinical Development of a Novel FcRn Antagonist in the Treatment of Autoimmune Diseases. SKIN The Journal of Cutaneous Medicine. 7(2). s193–s193. 1 indexed citations
6.
Bril, Vera, James F. Howard, Chafic Karam, et al.. (2023). Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study. European Journal of Neurology. 31(1). e16098–e16098. 12 indexed citations
7.
Ashcraft, Elizabeth E., Vera Bril, Mamatha Pasnoor, et al.. (2023). P277 Long-term safety, tolerability, and efficacy of Efgartigimod in patients with Generalized Myasthenia Gravis: concluding analyses from the ADAPT+ study. Neuromuscular Disorders. 33. S179–S179. 1 indexed citations
8.
Pasnoor, Mamatha, Vera Bril, Chafic Karam, et al.. (2023). Long-Term Safety, Tolerability, And Efficacy of Efgartigimod in Patients with Generalized Myasthenia Gravis: Concluding Analyses from the ADAPT+ Study (S5.006). Neurology. 100(17_supplement_2). 2 indexed citations
9.
Brinkhaus, Maximilian, Arthur E. H. Bentlage, Ninotska I. L. Derksen, et al.. (2022). The Fab region of IgG impairs the internalization pathway of FcRn upon Fc engagement. Nature Communications. 13(1). 6073–6073. 27 indexed citations
10.
Mané-Damas, Marina, et al.. (2022). Novel treatment strategies for acetylcholine receptor antibody-positive myasthenia gravis and related disorders. Autoimmunity Reviews. 21(7). 103104–103104. 13 indexed citations
11.
Howard, James F., Vera Bril, Tuan Vu, et al.. (2021). Efficacy, Safety, and Tolerability of Efgartigimod in Patients With Generalized Myasthenia Gravis: Analysis of the Phase 3 ADAPT Study (4520). Neurology. 96(15_supplement). 9 indexed citations
12.
Wolfe, Gil I., E. Sally Ward, Hans de Haard, et al.. (2021). IgG regulation through FcRn blocking: A novel mechanism for the treatment of myasthenia gravis. Journal of the Neurological Sciences. 430. 118074–118074. 39 indexed citations
13.
Huijbers, Maartje G., Jaap J. Plomp, Inge E. van Es, et al.. (2019). Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis. Experimental Neurology. 317. 133–143. 31 indexed citations
14.
Ulrichts, Peter, Antonio Guglietta, Torsten Dreier, et al.. (2018). Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. Journal of Clinical Investigation. 128(10). 4372–4386. 251 indexed citations
15.
Silence, Karen, Torsten Dreier, Mahan Moshir, et al.. (2013). ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade. mAbs. 6(2). 523–532. 76 indexed citations
16.
Ulrichts, Peter, A. De Smet, Dominiek Catteeuw, et al.. (2011). Identification of Interaction Sites for Dimerization and Adapter Recruitment in Toll/Interleukin-1 Receptor (TIR) Domain of Toll-like Receptor 4. Journal of Biological Chemistry. 287(6). 4088–4098. 57 indexed citations
17.
Ulrichts, Peter, Irma Lemmens, Delphine Lavens, Rudi Beyaert, & Jan Tavernier. (2009). MAPPIT (Mammalian Protein–Protein Interaction Trap) Analysis of Early Steps in Toll-Like Receptor Signalling. Methods in molecular biology. 517. 133–144. 9 indexed citations
18.
Ulrichts, Peter & Jan Tavernier. (2008). MAPPIT analysis of early Toll-like receptor signalling events. Immunology Letters. 116(2). 141–148. 9 indexed citations
19.
Ulrichts, Peter, Frank Peelman, Rudi Beyaert, & Jan Tavernier. (2007). MAPPIT analysis of TLR adaptor complexes. FEBS Letters. 581(4). 629–636. 23 indexed citations
20.
Peelman, Frank, Katrien Van Beneden, Lennart Zabeau, et al.. (2004). Mapping of the Leptin Binding Sites and Design of a Leptin Antagonist. Journal of Biological Chemistry. 279(39). 41038–41046. 121 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Balaji Balasa Breakdown of academic impact, for papers by Barbara A. Vance Breakdown of academic impact, for papers by Yuko Kozono Breakdown of academic impact, for papers by Toshimasa Nakagawa Breakdown of academic impact, for papers by Maria Hinterberger Breakdown of academic impact, for papers by Roberto González‐Amaro Breakdown of academic impact, for papers by Elinor Lee Breakdown of academic impact, for papers by D. Ockert Breakdown of academic impact, for papers by Anna Lena Illert Breakdown of academic impact, for papers by Claudia Müller
Rankless by CCL
2026